Bicycle Therapeutics Net Income
| BCYC Stock | USD 5.66 0.35 6.59% |
As of the 10th of February, Bicycle Therapeutics shows the mean deviation of 2.89, and Risk Adjusted Performance of (0.06). Bicycle Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Bicycle Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 21.2178 | Revenue | Earnings Share (3.62) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -152.1 M | -144.5 M | |
| Net Loss | -101.4 M | -96.4 M | |
| Net Loss | -152.1 M | -144.5 M | |
| Net Loss | (3.34) | (3.51) | |
| Net Income Per E B T | 1.12 | 1.09 |
Bicycle | Net Income | Build AI portfolio with Bicycle Stock |
Analyzing Bicycle Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Bicycle Therapeutics's current valuation and future prospects.
Latest Bicycle Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Bicycle Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Bicycle Therapeutics financial statement analysis. It represents the amount of money remaining after all of Bicycle Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Bicycle Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bicycle Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (169.03 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Bicycle Net Income Regression Statistics
| Arithmetic Mean | (61,186,819) | |
| Coefficient Of Variation | (103.63) | |
| Mean Deviation | 53,971,705 | |
| Median | (21,846,000) | |
| Standard Deviation | 63,405,121 | |
| Sample Variance | 4020.2T | |
| Range | 167.2M | |
| R-Value | (0.87) | |
| Mean Square Error | 1076.6T | |
| R-Squared | 0.75 | |
| Slope | (10,866,188) | |
| Total Sum of Squares | 64323.3T |
Bicycle Net Income History
Other Fundumenentals of Bicycle Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Bicycle Therapeutics Net Income component correlations
Bicycle Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Bicycle Therapeutics is extremely important. It helps to project a fair market value of Bicycle Stock properly, considering its historical fundamentals such as Net Income. Since Bicycle Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bicycle Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bicycle Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Bicycle diversify its offerings? Factors like these will boost the valuation of Bicycle Therapeutics. Projected growth potential of Bicycle fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Bicycle Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.62) | Revenue Per Share | Quarterly Revenue Growth 3.385 | Return On Assets | Return On Equity |
The market value of Bicycle Therapeutics is measured differently than its book value, which is the value of Bicycle that is recorded on the company's balance sheet. Investors also form their own opinion of Bicycle Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicycle Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Bicycle Therapeutics' market value can be influenced by many factors that don't directly affect Bicycle Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Bicycle Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bicycle Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bicycle Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Bicycle Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bicycle Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bicycle Therapeutics.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Bicycle Therapeutics on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Bicycle Therapeutics or generate 0.0% return on investment in Bicycle Therapeutics over 90 days. Bicycle Therapeutics is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that ar... More
Bicycle Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bicycle Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bicycle Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 14.2 | |||
| Value At Risk | (6.93) | |||
| Potential Upside | 6.06 |
Bicycle Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bicycle Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bicycle Therapeutics' standard deviation. In reality, there are many statistical measures that can use Bicycle Therapeutics historical prices to predict the future Bicycle Therapeutics' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.94) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bicycle Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bicycle Therapeutics February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.93) | |||
| Mean Deviation | 2.89 | |||
| Coefficient Of Variation | (1,207) | |||
| Standard Deviation | 3.72 | |||
| Variance | 13.81 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.94) | |||
| Maximum Drawdown | 14.2 | |||
| Value At Risk | (6.93) | |||
| Potential Upside | 6.06 | |||
| Skewness | (0.18) | |||
| Kurtosis | (0.14) |
Bicycle Therapeutics Backtested Returns
Bicycle Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0537, which signifies that the company had a -0.0537 % return per unit of standard deviation over the last 3 months. Bicycle Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Bicycle Therapeutics' mean deviation of 2.89, and Risk Adjusted Performance of (0.06) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.34, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bicycle Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bicycle Therapeutics is expected to be smaller as well. At this point, Bicycle Therapeutics has a negative expected return of -0.18%. Please make sure to confirm Bicycle Therapeutics' standard deviation, kurtosis, period momentum indicator, as well as the relationship between the maximum drawdown and day median price , to decide if Bicycle Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.04 |
Very weak reverse predictability
Bicycle Therapeutics has very weak reverse predictability. Overlapping area represents the amount of predictability between Bicycle Therapeutics time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bicycle Therapeutics price movement. The serial correlation of -0.04 indicates that only as little as 4.0% of current Bicycle Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.04 | |
| Spearman Rank Test | -0.48 | |
| Residual Average | 0.0 | |
| Price Variance | 0.22 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Bicycle Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Bicycle Therapeutics reported net income of (169.03 Million). This is 149.53% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 129.6% higher than that of the company.
Bicycle Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bicycle Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bicycle Therapeutics could also be used in its relative valuation, which is a method of valuing Bicycle Therapeutics by comparing valuation metrics of similar companies.Bicycle Therapeutics is currently under evaluation in net income category among its peers.
Bicycle Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Bicycle Therapeutics from analyzing Bicycle Therapeutics' financial statements. These drivers represent accounts that assess Bicycle Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Bicycle Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 343.7M | 1.5B | 878.0M | 643.5M | 579.2M | 559.2M | |
| Enterprise Value | 223.5M | 1.1B | 583.1M | 162.0M | 145.8M | 138.5M |
Bicycle Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bicycle Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bicycle Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Bicycle Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Bicycle Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Bicycle Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bicycle Therapeutics' value.| Shares | Bnp Paribas Investment Partners Sa | 2025-06-30 | 1 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1 M | Tybourne Capital Management (hk) Ltd | 2025-06-30 | 993.7 K | Bank Of America Corp | 2025-06-30 | 830.6 K | Principal Financial Group Inc | 2025-06-30 | 697.3 K | Jefferies Financial Group Inc | 2025-06-30 | 461.1 K | Woodline Partners Lp | 2025-06-30 | 362.3 K | Renaissance Technologies Corp | 2025-06-30 | 318.4 K | Junked Platinum Investment Management Ltd | 2025-06-30 | 285.4 K | Baker Bros Advisors Lp | 2025-06-30 | 10.9 M | Fcpm Iii Services Bv | 2025-06-30 | 3.5 M |
Bicycle Fundamentals
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (5.59) % | ||||
| Current Valuation | (249.96 M) | ||||
| Shares Outstanding | 49.93 M | ||||
| Shares Owned By Insiders | 1.39 % | ||||
| Shares Owned By Institutions | 78.97 % | ||||
| Number Of Shares Shorted | 1.95 M | ||||
| Price To Earning | (3.31) X | ||||
| Price To Book | 0.63 X | ||||
| Price To Sales | 13.85 X | ||||
| Revenue | 35.27 M | ||||
| Gross Profit | (210.9 M) | ||||
| EBITDA | (164.89 M) | ||||
| Net Income | (169.03 M) | ||||
| Cash And Equivalents | 372.77 M | ||||
| Cash Per Share | 12.56 X | ||||
| Total Debt | 9.49 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 9.88 X | ||||
| Book Value Per Share | 8.92 X | ||||
| Cash Flow From Operations | (164.72 M) | ||||
| Short Ratio | 7.81 X | ||||
| Earnings Per Share | (3.62) X | ||||
| Target Price | 21.1 | ||||
| Number Of Employees | 305 | ||||
| Beta | 1.64 | ||||
| Market Capitalization | 392.62 M | ||||
| Total Asset | 956.87 M | ||||
| Retained Earnings | (680.79 M) | ||||
| Working Capital | 861.38 M | ||||
| Current Asset | 103.53 M | ||||
| Current Liabilities | 8.46 M | ||||
| Net Asset | 956.87 M |
About Bicycle Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bicycle Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bicycle Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bicycle Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bicycle Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bicycle Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bicycle Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bicycle Therapeutics Stock:Check out For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Will Biotechnology sector continue expanding? Could Bicycle diversify its offerings? Factors like these will boost the valuation of Bicycle Therapeutics. Projected growth potential of Bicycle fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Bicycle Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.62) | Revenue Per Share | Quarterly Revenue Growth 3.385 | Return On Assets | Return On Equity |
The market value of Bicycle Therapeutics is measured differently than its book value, which is the value of Bicycle that is recorded on the company's balance sheet. Investors also form their own opinion of Bicycle Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicycle Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Bicycle Therapeutics' market value can be influenced by many factors that don't directly affect Bicycle Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Bicycle Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bicycle Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bicycle Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.